Vaxdyn — Series A · €11M

The Seville-area biotech raised €11M to take K-VAX, its vaccine against multidrug-resistant Klebsiella pneumoniae and Acinetobacter baumannii, into a Phase 1 trial. Biovance Capital led with €4M and Arcano Partners' Impacto Andalucía fund put in €3.6M, complemented by €3.2M of non-dilutive EIC Accelerator money.

LeadBiovance Capital RoundSeries A Announced7 Sep 2026 CitySevilla · reported Dos Hermanas SectorHealthtech & Bio · Biotech / vaccines Source W E E E

Something wrong? Suggest a correction →